148 related articles for article (PubMed ID: 7642336)
1. Full-thickness macular holes treated with vitrectomy and tissue glue.
Tilanus MA; Deutman AF
Int Ophthalmol; 1994-1995; 18(6):355-8. PubMed ID: 7642336
[TBL] [Abstract][Full Text] [Related]
2. Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2.
Thompson JT; Hiner CJ; Glaser BM; Gordon AJ; Murphy RP; Sjaarda RN
Am J Ophthalmol; 1994 Mar; 117(3):291-301. PubMed ID: 8129001
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
Blumenkranz MS; Ohana E; Shaikh S; Chang S; Coll G; Morse LS; De Bustros S
Ophthalmic Surg Lasers; 2001; 32(3):198-207. PubMed ID: 11371086
[TBL] [Abstract][Full Text] [Related]
4. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes.
Lansing MB; Glaser BM; Liss H; Hanham A; Thompson JT; Sjaarda RN; Gordon AJ
Ophthalmology; 1993 Jun; 100(6):868-71; discussion 871-2. PubMed ID: 8510899
[TBL] [Abstract][Full Text] [Related]
5. Surgical treatment of full-thickness macular holes using autologous serum.
Wells JA; Gregor ZJ
Eye (Lond); 1996; 10 ( Pt 5)():593-9. PubMed ID: 8977788
[TBL] [Abstract][Full Text] [Related]
6. The results of vitreous surgery for chronic macular holes.
Thompson JT; Sjaarda RN; Lansing MB
Retina; 1997; 17(6):493-501. PubMed ID: 9428011
[TBL] [Abstract][Full Text] [Related]
7. The role of vitreoretinal surgery in the treatment of posttraumatic macular hole.
García-Arumí J; Corcostegui B; Cavero L; Sararols L
Retina; 1997; 17(5):372-7. PubMed ID: 9355183
[TBL] [Abstract][Full Text] [Related]
8. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.
Minihan M; Goggin M; Cleary PE
Br J Ophthalmol; 1997 Dec; 81(12):1073-9. PubMed ID: 9497468
[TBL] [Abstract][Full Text] [Related]
9. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP
Am J Ophthalmol; 1995 Jan; 119(1):48-54. PubMed ID: 7825689
[TBL] [Abstract][Full Text] [Related]
10. Value of internal limiting membrane peeling in surgery for idiopathic macular hole and the correlation between function and retinal morphology.
Christensen UC
Acta Ophthalmol; 2009 Dec; 87 Thesis 2():1-23. PubMed ID: 19912135
[TBL] [Abstract][Full Text] [Related]
11. Treatment of idiopathic macular holes by induced posterior vitreous detachment.
Chan CK; Wessels IF; Friedrichsen EJ
Ophthalmology; 1995 May; 102(5):757-67. PubMed ID: 7777275
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.
Glaser BM; Michels RG; Kuppermann BD; Sjaarda RN; Pena RA
Ophthalmology; 1992 Jul; 99(7):1162-72; discussion 1173. PubMed ID: 1495798
[TBL] [Abstract][Full Text] [Related]
13. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group.
Freeman WR; Azen SP; Kim JW; el-Haig W; Mishell DR; Bailey I
Arch Ophthalmol; 1997 Jan; 115(1):11-21. PubMed ID: 9006420
[TBL] [Abstract][Full Text] [Related]
14. [Visual development of postoperative persistent macular holes with and without surgical revision].
Schüler A; Lucke K; Bopp S
Klin Monbl Augenheilkd; 2009 Nov; 226(11):927-32. PubMed ID: 19798626
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade.
Rosa RH; Glaser BM; de la Cruz Z; Green WR
Am J Ophthalmol; 1996 Dec; 122(6):853-63. PubMed ID: 8956640
[TBL] [Abstract][Full Text] [Related]
16. Correlation of quantitative three-dimensional measurements of macular hole size with visual acuity after vitrectomy.
Kobayashi H; Kobayashi K
Graefes Arch Clin Exp Ophthalmol; 1999 Apr; 237(4):283-8. PubMed ID: 10208260
[TBL] [Abstract][Full Text] [Related]
17. Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes.
Rubin JS; Glaser BM; Thompson JT; Sjaarda RN; Pappas SS; Murphy RP
Ophthalmology; 1995 Dec; 102(12):1840-5. PubMed ID: 9098285
[TBL] [Abstract][Full Text] [Related]
18. Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study.
Ie D; Glaser BM; Thompson JT; Sjaarda RN; Gordon LW
Ophthalmology; 1993 Dec; 100(12):1787-93. PubMed ID: 8259275
[TBL] [Abstract][Full Text] [Related]
19. Vitrectomy with internal limiting membrane (ILM) peeling versus vitrectomy with no peeling for idiopathic full-thickness macular hole (FTMH).
Spiteri Cornish K; Lois N; Scott N; Burr J; Cook J; Boachie C; Tadayoni R; la Cour M; Christensen U; Kwok A
Cochrane Database Syst Rev; 2013 Jun; (6):CD009306. PubMed ID: 23740611
[TBL] [Abstract][Full Text] [Related]
20. [Atypical macular holes].
Brüggemann A; Hoerauf H
Klin Monbl Augenheilkd; 2008 Apr; 225(4):281-5. PubMed ID: 18401794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
